Papillary Thyroid Carcinoma with Different Histological Patterns

Jen-Der Lin, MD; Chuen Hsueh¹, MD; Bie-Yu Huang, MD

Tumor-node-metastasis (TNM) staging is the most commonly used model for evaluating therapeutic strategies for papillary thyroid cancer (PTC). Additionally, different histopathological patterns and variants of PTC have been reported to influence the prognosis of these patients. We reviewed the clinical presentation, cancer recurrence, and cancer-specific mortality of the most frequent histological patterns, including the follicular variant (FVPTC), insular pattern, tall cell pattern, diffuse sclerosing type, PTC with Hashimoto’s thyroiditis, and multicentric PTC. The tall cell variant of PTC is a more aggressive variant than classical PTC and has a poor prognosis. The high expression of Muc1 and type IV collagenase in these tumors may facilitate stromal degradation and increase the invasive potential. In contrast, approximately 18% of PTC patients have been identified as having FVPTC. FVPTC patients have a better survival rate than those with follicular thyroid cancer, and fewer instances of lymph node or soft tissue invasion than control patients with classical PTC. The diffuse sclerosing variant of PTC predominantly observed in young patients is a rare aggressive tumor that requires intensive treatment. Despite characteristic clinical and histological features that facilitate easy diagnosis, pre-operative fine needle aspiration cytological diagnosis of this variant is often challenging. Different histological variants of PTC with other histological patterns are important for predicting cancer recurrence. In addition to TNM staging, high-risk histological patterns of PTC require more aggressive follow-up examinations and postoperative adjuvant therapies. (Chang Gung Med J 2011;34:23-34)

Key words: total thyroidectomy, thyroglobulin, cancer recurrence, poorly differentiated thyroid cancer

Papillary thyroid carcinoma (PTC) is the most commonly observed well-differentiated thyroid cancer in endocrine clinics. Most PTC patients have a good prognosis and long-term survival without distant metastasis. Tumor-node-metastasis (TNM) staging is most commonly used for the initial evaluation of thyroid cancer before and after thyroid surgery. Furthermore, different histopathological patterns and variants of PTC have been reported to influence the prognosis of these patients. During the last 10 years, PTC has gained increasing attention as a result of its rising incidence and better survival rates. Despite this, the identification of specific variants of PTC with distinct clinical outcomes and pathological features is important. In this review, we will focus on the histological patterns and variants of PTC and their implications for treatment and follow-up.
years, data have accumulated from long-term follow-up studies of different histological patterns and variants of PTC.

As indicated in a recent investigation, new variants of PTC or other histological patterns may correlate with patient prognosis. The most frequent histological patterns such as the follicular variant, insular pattern, columnar, tall cell pattern, diffuse sclerosing type, Hashimoto’s thyroiditis, and multicentric PTC were categorized. The purpose of this review is to stratify the prognosis concerning cancer recurrence and cancer mortality in PTC patients with different histopathological patterns compared with those with classical PTC. Different variants or histological patterns may co-exist in a patient.

We have not had sufficient information about different histological variants of PTC in reports from different populations and countries. The biological behaviors of PTC variants differ from that of classical PTC. A recent report observed follicular, tall cell, and oncocytic variants at comparably high rates of 6.6%, 3.9%, and 1.9%, respectively. Disease-free survival and cause-specific survival rates in patients with the tall cell variant were significantly worse than those in patients with classical PTC. Inconsistent data concerning variants of PTC may have been generated by inconsistent diagnostic criteria and differences in characteristics, such as the gender, age, geographic location and ethnic background, of subjects enrolled in analyses. The reported histological variants of PTC in children and adolescents differ from those in adults. A series of 42 PTC patients found 8 (19%) with non-specified PTC, 12 (29%) with the solid/trabecular variant, 7 (16%) with the microcarcinoma variant, 6 (14%) with the diffuse sclerosing variant, 4 (10%) with the follicular variant, 2 (5%) with the encapsulated follicular variant, and 3 (7%) with the tall cell variant.

**Different histological patterns with papillary thyroid cancer**

**Tall cell variant**

The tall cell variant of PTC is defined by cells that are at least twice as high as they are wide. Histopathological findings show the tumors to be extremely papillary, and the papillae are elongated and occasionally coalescent (Fig. 1A). The low-power microscopic appearance may resemble a trabecular pattern in parts of the tumor. Since the first report of the variant by Hawk and Hazard in 1976, clinicians have struggled with this variant because pathologists have had difficulty in recognizing the tumor and misdiagnosing this variant. In a study performed in a large academic center, 12% of classical PTC patients without extra-thyroid extension were reclassified as having the tall cell variant. The major discrepancy in the diagnosis among pathologists is the percentage of tall cells in pathological slides. In previous studies, rates of 10 to 70% were reported. Patients diagnosed with the tall cell variant of PTC were older at presentation and had large tumors with extra-thyroid extension compared with those with classic PTC. Indeed, in one study, 80% of the patients with the tall cell variant showed some degree of extra-thyroid extension, and the mean age at presentation was 53 years. A diagnosis of the tall cell variant of PTC is made when ≥ 50% of cells are tall cells. As mentioned previously, the cells should have a height that is at least twice their width, an eosinophilic cytoplasm, and the nuclear features of PTC.

Although fine needle aspiration cytology (FNAC) is of limited value in typing the variants of PTC because of overlapping morphological features, it can provide clues for diagnosing certain aggressive variants. Cytological features of the tall cell variant included cleaved nuclei with fine powdery chromatin, small nucleoli, and a dense oxyphilic cytoplasm. Nuclear grooves and intranuclear cytoplasmic pseudoinclusions are rare. The striking cytological features are “tail-like cells” that contain tall, columnar, and oxyphilic cytoplasmic regions with eccentric nuclei located adjacent to the basement membrane (Fig. 1B). The reported differential diagnosis of the tall cell variant of PTC includes Hürthle cell lesions, oncocytic PTC, Warthin-like papillary carcinoma, and breast cancer. There is overlap in the morphologic features of the tall cell and Hürthle cell variants, and in one study, cytology correctly identified 60% and 76.4% of these cases, respectively.

Ghossein et al. reported that the gland-confined tall cell variant of PTC without extrathyroid extension has a more aggressive behavior than conventional intrathyroidal PTC. Patients with the tall cell variant without extrathyroidal extension were shown to have a significantly higher nodal metastatic rate than patients with classical PTC patients without...
extrathyroidal extension, independent of age, gender, and tumor size \( (p = 0.004) \). In that same study, 3 of 47 (6%) patients with the tall cell variant without extrathyroidal extension developed distant metastases, while none of the 62 patients with classical PTC had recurrence at a distant site \( (p = 0.07) \). In a recent study at the Memorial Sloan-Kettering Cancer Center, 278 patients with the tall cell variant presented at an older age (54.3 years vs. 46.3 years, \( p < 0.0001 \)) and had a higher rate of extrathyroidal extension (53.6% vs. 30.2%, \( p < 0.0001 \)) and poorer 5-year disease-specific survival (81.9% vs. 97.8%, \( p < 0.0001 \)) than 2,522 classical PTC patients with sufficient information for analysis. \(^{16} \) Patients with the tall cell variant had poorer 5-year disease-specific survival (81.9% vs. 91.3%, \( p = 0.049 \)) and a higher number of deaths \( (p = 0.043) \) than a matched PTC cohort.

There is still a paucity of information from long-term follow-up cases of small tumors and the tall cell variant confined to the lymph node. The implications of tall cell microcarcinoma have not been addressed in the literature, as these tumors are extremely rare and long-term follow-up data on large numbers of patients are not available. No study has addressed the prognostic impact of cervical nodal metastases comprised of tall cells in patients whose primary tumor is of the classical type.

Although there are several reports on the association between the molecular profile of these tumors and the aggressive behavior of the tall cell variant of PTC, host factors, other tumor factors and tumor–tall cell variant-host interactions remain unknown. Some data appear to indicate that molecular factors intrinsic to the tall cell variant are responsible for its aggressive biological and clinical behavior. The aggressive behavior of the tall cell variant could be related to certain factors elaborated by the tumor. The high expression of Muc1 and type IV collagenase (matrix metalloproteinase-2) in these tumors may allow for stromal degradation and greater invasive potential.\(^{20,21} \) The high Ki-67 (MIB-1) labeling index noted in an immunohistochemistry study, suggesting higher proliferation activity of the tall cell variant than classical PTC, has been investigated in cases of extrathyroidal invasion.\(^{16} \) The aggressive behavior of the tall cell variant may also be related to the higher prevalence of activating point mutations of BRAF in the tall cell variant than in classical PTC.\(^{21} \) Indeed, papillary cancers of any subtype that have BRAF mutations have a higher frequency of extraglandular extension and nodal metastases. The incidence of the tall cell variant is accentuated by the fact that it is over-represented in thyroid carcinomas that are refractory to radioactive iodine (RAI) therapy. Recently, Rivera et al. found that 20% of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-positive/RAI refractory tumors were the tall cell variant type.\(^{22} \)

**Follicular variant**

In 1977, Chen et al. observed a follicular variant of PTC (FVPTC) exhibiting the characteristic biological behavior and morphological features of PTC.\(^{23} \) Approximately 18% (42 of 227 patients) of
patients with PTC were identified as having FVPTC. Clinical and laboratory analyses have indicated the existence of separate mechanisms and routes for distant metastasis and either extrathyroidal growth or lymph node metastasis of thyroid cancer. A high proportion of PTC patients have extrathyroidal growth or lymph node metastasis; conversely, follicular thyroid cancer results in more distant metastases than PTC. FVPTC patients have a better survival rate than follicular thyroid cancer patients and fewer instances of lymph node and soft tissue invasion than control patients with classical PTC.

The preoperative diagnosis of FVPTC has been investigated and analyzed in recent decades. The diagnostic features revealed by FNAC are thick eosinophilic colloid balls in the background, multilayered microfollicles (rosettes), numerous grooves, and inclusions in follicular cell monolayers (Fig. 2). All cytological analyses of FVPTC, including those by Goodell et al. from the US, Nair et al from India, Fulciniti et al from Italy, and Kumar et al from Iran were retrospective studies that attempted to identify the cytopathological correlation between FVPTC and other thyroid malignancies with small sample sizes.

A cross-sectional population analysis of a national cancer database in the U.S.A. that examined the prevalence and extent of disease characteristics of FVPTC and the survival impact of its histopathological diagnosis compared to classical PTC illustrated that age at presentation and sex distribution were similar between FVPTC (47.9 years; 79.3% female) and classical PTC patients. Although the prevalence of lymph node metastasis was significantly lower in FVPTC than classical PTC (14.8% vs. 27.8%, respectively; \( p < 0.001 \)), the T stage was not significantly different (\( p = 0.450 \)). The mean overall survival rates for patients with FVPTC (204.5 months) and classical PTC (205.3 months) were not significantly different (\( p = 0.373 \)). Most long-term follow-up studies in other populations showed similar survival rates for these two diseases; in addition, the aggressive macrofollicular variant of PTC was reported in limited cases.

Despite the good prognosis of FVPTC compared with the classical form of PTC, the pre-operative diagnosis and diagnosis of FVPTC from frozen sections are still challenging. Before the histopathologic criteria for FVPTC were utilized universally, there was controversy concerning the diagnostic criteria for minimally invasive follicular thyroid cancer, FVPTC, and follicular adenoma. After a review of previous pathological findings in one study, 25% of patients had a change in diagnosis. Theoretically, there is a possibility of FVPTC or minimally invasive follicular thyroid cancer being diagnosed as benign lesions; additionally, some distant metastases are found years later in follow-up evaluations. For these patients, additional histological analysis using frozen sections or final histopathological diagnoses is recommended.

**Diffuse sclerosing pattern**

The diffuse sclerosing type of PTC is characterized by diffuse involvement of 1 or both lobes of the thyroid, marked squamous metaplasia, numerous psammoma bodies, extensive interstitial fibrosis, and heavy lymphocytic infiltration with formation of germinal centers. The diffuse sclerosing variant of PTC is a rare and aggressive tumor that requires intensive treatment. Despite characteristic clinical and histological features that permit easy diagnosis, pre-operative FNAC diagnosis is often challenging and inexperienced cytopathologists can delay the diagnosis.

Fig. 3 illustrates a 25 year-old woman who presented with a left thyroid nodule. The thyroid ultrasound showed a hypoechoic nodule with an ill-defined margin (Fig. 3A). A previous imaging inves-
igation of 8 patients revealed the following ultrasound features (7/8) of the diffuse sclerosing variant of PTC: heterogeneous echotexture (7/7), solid composition (7/7), ill-defined margins (4/7), scattered microcalcifications with a snowstorm appearance (7/7), and various echogenicities. CT findings (6/8) revealed numerous microcalcifications and multiple enlarged nodes in all of the patients. These imaging studies are not specific for the diffuse sclerosing variant of PTC. Further cytological examination was important in this woman. FNAC demonstrated monolayer cells with anisocytosis and mitotic figures in a Liu stain (Fig. 3B). After a total thyroidectomy with lymph node dissection, an RAI whole-body scan revealed lung metastases in the patient. Evaluation of this patient showed that the diffuse sclerosing variant is a major subtype of PTC in the young, as was also shown in a recent report. The histology of this tumor is characterized by diffuse involvement of 1 or both lobes of the thyroid, with many psammoma bodies, dense lymphocytic infiltrates and scattered lymphoid follicles (Fig. 3C, D).

Because the diffuse sclerosing variant of PTC is not common, it was not until about 10 years ago that long-term treatment results could be analyzed. In 1990, 14 patients treated between 1958 and 1988 for the diffuse sclerosing variant of PTC were shown to be alive without metastasis. The study concluded that complete resection did not result in later recurrence in any of the patients; therefore, cosmetic and complication-free surgery should be considered. Further investigation illustrated cancer mortality was not changed; additionally, the rates of recurrence and distant metastases were increased compared with those for classical PTC patients. A large series study consisting of 83 patients with the diffuse sclerosing variant of PTC and 168 patients with classical PTC illustrated that the incidence of laterocervical lymph node pathology at diagnosis was significantly higher for the diffuse sclerosing variant (p < 0.05). Recurrences in regional lymph nodes were observed in 3.6% and 15.7% (p < 0.001), and distant metastases in 1.2% and 7.2% (p < 0.05) of classical PTC and the diffuse sclerosing variant of PTC, respectively. One patient with classical PTC (0.6%) and 3 with the diffuse sclerosing variant (3.6%) died from tumor-related causes (p < 0.05). In summary, the diffuse sclerosing variant of PTC is an uncommon

![Fig. 3](image-url) Thyroid ultrasonography (A), fine needle aspiration cytology (B) with Liu’s stain and histopathological findings (C, D) in a 25 year-old woman histologically diagnosed with the diffuse sclerosing variant of papillary thyroid carcinoma.
thyroid cancer that is predominantly diagnosed in young patients, but its clinical behavior is highly aggressive. Therefore, more aggressive surgical treatment with appropriate postoperative $^{131}$I therapy is recommended.

**Papillary thyroid carcinoma with chronic lymphocytic thyroiditis**

Both PTC and chronic lymphocytic thyroiditis or Hashimoto’s thyroiditis are commonly observed in endocrine clinics. The interrelationship between these disorders concerning their occurrence, clinical presentation, diagnosis, and therapeutic results has been presented by several centers. Asymptomatic and subclinical chronic thyroiditis are not generally detected early except in subjects who have health screenings. Imaging analysis including thyroid ultrasonography is used less frequently in patients diagnosed with chronic lymphocytic thyroiditis. For these reasons, the association of chronic lymphocytic thyroiditis with PTC was only revealed a decade ago. In addition, the diffuse hypoechogenicity of chronic lymphocytic thyroiditis in thyroid ultrasound imaging makes the diagnosis of malignant lesions in the thyroid difficult.

There are ethnic, geographic, and gender differences in the prevalence of PTC with chronic lymphocytic thyroiditis. After the first documentation by Dailey et al. in 1955, the reported rate of coexistence of these 2 diseases ranged from 0.3 to 38%. The relationship between these two conditions remains unclear because it is controversial whether chronic lymphocytic thyroiditis is induced secondarily by the neoplasm or whether it predisposes the patient to development of thyroid carcinoma. Despite the difference in etiology of these 2 disorders, the prevalence and severity of chronic lymphocytic thyroiditis combined with 3 other diseases was defined by examination of surgically resected materials from 3 ethnic groups. The incidence of autoimmune thyroiditis was significantly higher in patients with PTC than in those with adenomatous goiters or follicular adenoma. Most studies have shown better clinical presentations, less frequent recurrences, and lower cancer mortality in PTC patients with coexisting chronic lymphocytic thyroiditis than in those without it. PTC associated with chronic lymphocytic thyroiditis is associated with a smaller primary tumor size at presentation. It is also associated with a reduced risk of recurrence during follow-up, although this was not significant after adjustment for other prognostic factors. A BRAF (V600E) mutation in PTC cells was revealed as a factor that facilitates tumor cell growth and progression. The mutation results in a more advanced clinical presentation and poor prognosis for PTC patients after treatment. The prevalence of activating point mutations in BRAF is much higher (73 - 86%) in Korea than in Western countries (29-69%), and these mutations are associated with a poor prognosis in PTC patients. Further investigation is required to determine the frequency of the BRAF (V600E) mutation in PTC patients with and without coexisting chronic lymphocytic thyroiditis and the clinical and pathological features associated with concomitant chronic lymphocytic thyroiditis and PTC. Previous findings revealed that the BRAF (V600E) mutation was present in 27 (72.9%) patients with and 61 (95.3%) patients without chronic lymphocytic thyroiditis ($p = 0.01$). The low mutation frequency partially explains the better prognosis in PTC patients with chronic lymphocytic thyroiditis.

**Poorly differentiated pattern of papillary thyroid cancer**

Poorly differentiated thyroid carcinoma, an undifferentiated carcinoma similar to medullary carcinoma, is a lethal invasive thyroid cancer. Histopathological examination of PTC and follicular thyroid cancer may reveal poorly differentiated thyroid carcinoma in a primary thyroid operation or tissues with recurrence. These dedifferentiations may result in a poor prognosis for patients. Characteristic histological patterns such as trabecular insular and solid areas, growth patterns of atypias and necrosis, and high mitotic counts have been used as diagnostic criteria. Few reports and studies of poorly differentiated thyroid carcinoma pathogenesis have been published. A recent examination of 111 differentiated thyroid carcinoma patients with distant metastases identified poor differentiation as an independent factor associated with poor outcome. Foci of poorly differentiated tumors have been identified through pathological analysis in cases of thyroid carcinoma that are predominantly well-differentiated. Immunohistochemical investigation of poorly differentiated thyroid carcinoma illustrates a follicu-
Papillary thyroid cancer

A lar-derived tumor, with thyroglobulin (Tg) production in intracellular paranuclear vacuoles and TTF-1 expression. Poorly differentiated thyroid carcinoma is classified based on the assumption that a lack of follicles is synonymous with a loss of normal thyroid structure. From a functional or endocrine point of view, the majority of poorly differentiated thyroid carcinomas maintain their capacity to produce hormones, and Tg is an important immunohistochemical marker for the differential diagnosis from other trabecular lesions of the thyroid gland but have no practical diagnostic application, as morphological signs of malignancy (i.e. vascular invasion) are unequivocally present in all patients. Markers of malignancy in follicular tumors (such as HBME-1 and galectin-3) may also be expressed in poorly differentiated thyroid carcinoma but have no practical diagnostic application, as morphological signs of malignancy (i.e. vascular invasion) are unequivocally present in all patients.

RAI uptake by cancer cells of poorly differentiated thyroid carcinomas is associated with successful 131I radiotherapy. In contrast, poorly differentiated thyroid carcinoma has been reported to be RAI - refractory and FDG-PET - positive. This difference reflects geographical variations in terms of different tumor stages at the time of 131I treatment and different timings and dosages for RAI administration. A recent investigation illustrated the high prevalence of the poorly differentiated thyroid carcinoma histotype in a series of 131I - refractory metastatic thyroid cancers, and in this specific subgroup of patients, the presence of necrosis and extrathyroidal extension was associated with shorter disease-specific survival. Early cytological diagnosis of poorly differentiated thyroid carcinoma followed by total thyroidectomy with tumor removal was the most effective therapy. Long-term follow-up studies revealed a 10-year cause-specific survival rate of 31% in poorly differentiated thyroid carcinoma patients. Age and TNM staging at the time of surgery were significant indicators of patient survival and mortality.

Multicentric papillary thyroid cancer

In PTC, multicentric lesions are not unusual findings. It is unclear whether tumor foci result from intraglandular metastases from a single dominant tumor or unrelated neoplastic clones. Clinical information concerning presentation and prognosis is needed, and long-term follow-up studies after treatment for multicentric PTC must be performed to determine the appropriate therapy.

Patients with multicentric PTC in previous studies were older and had more advanced clinical presentations and higher recurrence rates than patients with unifocal PTC. Multicentric PTC in association with radiation exposure and a familial history of Gardner’s syndrome results in a poorer prognosis than that observed for classical unifocal PTC. Over 30% of PTC was found to be multicentric and most may be associated with papillary microcarcinoma. According to previous data, 3.5% - 6.2% of PTC patients have a family history of thyroid cancer. Most multicentric PTC cases are sporadic and cannot be associated with previous radiation exposure. The preoperative diagnosis of multicentric PTC by thyroid ultrasonography with FNAC from multiple foci was evaluated in one study. Because these are high-risk patients, total thyroidectomy followed by 131I therapy and close follow-up of serum Tg levels is recommended for these multifocal small thyroid cancers. When lymph node metastases are identified during initial thyroid surgery, high rates of recurrent lymph node metastasis can be expected. Routine lymph node dissection or modified radical neck dissection is reported to reduce recurrence in these patients. 131I therapy is less effective for local neck recurrence.

Multicentric PTC presents with high recurrence rates and advanced TNM staging compared with unifocal PTC. Microcarcinoma in multicentric PTC should be treated as high-risk tumors. Persistent multicentric PTC results in high rates of recurrence and distant metastasis in patients and warrants aggressive therapeutic modalities.

Conclusions

TNM staging is still the most important guideline to determine postoperative therapy and follow-up for PTC. However, histological variants and a combination of PTC with other histological patterns have been shown to be important predictors of cancer recurrence.

Acknowledgements

The authors would like to thank Dr. WH Chen for cytological photographic contributions, Miss ML Perng for preparing the manuscript and Chang Gung Medical Center for supporting this research through
grant CMRPG380691.

REFERENCES

3. Koo JS, Hong S, Park CS. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid 2009;19:1225-31.


53. Kim EY, Kim WG, Kim WB, Kim TY, Kim JM, Ryu JS, Hong SJ, Gong G, Shong YK. Coexistence of chronic lymphocytic thyroiditis is associated with lower recur-


不同組織亞型之乳突狀甲狀腺癌

林仁德 薛 純 黃碧玉

腫瘤—淋巴—轉移 (TNM) 之分期，目前在乳突狀甲狀腺癌之臨床分期上是最常用的方式，在評估治療效果也較為客觀。在此分期分期背後並未把不同甲狀腺乳突癌組織亞型包含在內。在過去報告中不同組織亞型治療之預後差異極大。本文對乳突狀甲狀腺癌較常見之亞型或合併甲狀腺乳突癌之甲狀腺組織特殊型態如：濺泡型乳突癌，岛嶼型型 (Insulin Pattern)之未分化乳突癌，高細胞亞型及纖維硬化性亞型，與嚥本氏甲狀腺炎並存之乳突癌，與多發性甲狀腺乳突癌等。在臨床表徵，甲狀腺癌再發，或癌症之死亡率有回溯性之資料分析並可提供台灣一醫學中心之資料，以供比較。高細胞亞型在臨床上是較有侵犯性且預後較差之甲狀腺乳突癌。此亞型之癌細胞在 Mucl 及第 IV 型之 collagenase 之基因表達較強因而也使癌細胞對細胞外基質之穿透力增加且有較強之軟組織侵犯性。相對地，有 18% 之乳突狀甲狀腺癌是屬於濺泡狀亞型。濺泡狀亞型乳突癌治療之預後比濺泡狀甲狀腺癌佳，同時診斷時淋巴腺轉移或軟組織之侵犯比率比典型之乳突癌較少。纖維性硬化型之乳突癌發生在年輕人之侵犯性乳突癌，因而需較積極治療。儘管不同乳突癌之亞型臨床特徵及組織學性質差異很大，但手術前細針穿刺細胞學檢查並非容易診斷。不同組織亞型組織型態之病理學診斷在病人治療預後之判断是非常重要指標。因而在甲狀腺癌病人治療之建議上除在 TNM 分期外，組織亞型之判讀對術後積極性之輔助治療法是很重要的。(長庚醫誌 2011;34:23-34)

關鍵詞：甲狀腺全切除術，甲狀腺球蛋白，癌死亡，分化不良甲狀腺癌